The UK's ~80-centre NHS nephrology biopsy network and the Renal Association's guideline committee, not a broad specialist base, are the two structures that determine who actually influences IgA nephropathy prescribing.
IgA nephropathy is the UK's second most common primary glomerulonephritis, affecting an estimated 10,000 to 15,000 patients and driving 10 to 12% of incident end-stage renal disease. Diagnosis runs through a defined network: roughly 80 NHS specialist nephrology centres perform the confirmatory kidney biopsy the Renal Association's guideline requires before a patient is coded as IgAN. That concentration means influence over prescribing is structural rather than dispersed. Our KOL Universe gate (K1) starts by mapping this network, not by counting nephrologists in isolation.
The single most important entity for pre-launch engagement is the Renal Association's IgAN guideline committee itself. Its 2023 guideline, aligned with KDIGO 2021, sets ACEi and ARB optimisation as the mandatory pre-novel-agent step, and NICE has already built two technology appraisals, TA937/TA1128 for budesonide and TA1074 for sparsentan, directly against that committee's clinical framework. Engaging the guideline committee 18 to 24 months ahead of a NICE submission is not a discretionary relationship-building step: it is the point at which a manufacturer's evidence package is measured against the standard the committee itself set. Our Engagement Readiness gate (K4) sequences outreach against that submission timeline rather than a generic MSL calendar.
The UK IgAN institutional structure: an ~80-centre NHS biopsy network and one guideline-setting committee
| Structure | Role | Engagement Relevance |
|---|---|---|
| Renal Association IgAN guideline committee | Sets national clinical recommendations aligned with KDIGO 2021; direct NICE reference point | Primary pre-submission engagement target, 18-24 months ahead of NICE filing |
| NHS specialist nephrology centres (~80 nationally) | Perform confirmatory kidney biopsy required for IgAN diagnosis | Diagnostic gateway; territory coverage anchor for MSL deployment |
| NICE technology appraisal committee (TA937/TA1128/TA1074 precedent) | Sets the cost-effectiveness and evidentiary bar for novel IgAN agents | Downstream of guideline-committee engagement; not a separate outreach target |
Sources: UK Renal Registry 2023 annual report; Renal Association IgAN guideline 2023; NICE TA937/TA1128 (budesonide) and TA1074 (sparsentan); NICE GID-TA10820 IgAN scoping document.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The ~80-centre NHS nephrology biopsy network map
- the Renal Association guideline committee's role as NICE's clinical reference point
- K1 KOL Universe Sizing methodology
Delivers
- The 18-24 month engagement window
- K2 Tier Classification and K4 Engagement Readiness scoring
- sequencing against the NICE TA937/TA1128/TA1074 precedent
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live cross-checks against Renal Association and UK Renal Registry publications
- why no name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why the Renal Association guideline committee, not a broad specialist base, is the single variable this workbook sizes first
- Pressure-tested against the ~80-centre NHS biopsy network before the rest of the workbook is built out
- Every UK IgAN institutional stakeholder sized and sourced from Renal Association and UK Renal Registry publication data
- The ~80-centre NHS nephrology biopsy network as the sizing anchor
- Universe boundaries: guideline-committee influence versus high-volume biopsy centres
- Scientific-influence scoring across guideline-committee membership and NICE technology appraisal engagement
- What separates guideline-setting influence from high-volume biopsy throughput
- Influence inputs: guideline authorship, NICE TA submission engagement, institutional referral role
- Cross-checked against independent publication and NICE appraisal documentation
- Readiness scoring and the 18-24 month pre-submission engagement window
- Sequencing implications against the NICE TA937/TA1128/TA1074 precedent
- Territory-to-centre coverage map across the ~80-centre NHS nephrology network
- Where current MSL deployment has gaps
- Reach for institutions and committee members active beyond the NHS network, including KDIGO alignment
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session ahead of NICE submission
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name or institutional role ships without a verification tag.
UK IgA nephropathy KOL sources: UK Renal Registry 2023 annual report, the Renal Association IgAN guideline (2023, aligned with KDIGO 2021), NICE TA937/TA1128 and TA1074 decisions, and the NICE GID-TA10820 scoping document.
- UK Renal Registry patient and ESRD-share figures verified against the UK Renal Registry 2023 annual report
- Renal Association guideline committee role and the ACEi/ARB optimisation pathway verified against the Renal Association IgAN guideline 2023
- NICE TA937/TA1128 (budesonide) and TA1074 (sparsentan) status verified against published NICE technology appraisal decisions
- Every institutional entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams preparing a UK IgA nephropathy NICE submission. Custom workbook in 72 hours.
Specify your indication, geography, and submission timeline.
AXLRx analyst confirms institutional scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.